New Search

If you are not happy with the results below please do another search

1122 search results for:

335

EUROIMMUN introduces two new automation solutions for molecular diagnostics

EUROIMMUN introduces two new automation solutions for molecular diagnostics Molecular diagnostic analyses using EUROArray tests can now be completely automated with the introduction of two new devices. The Automated Workstation Pre-NAT II provides fully automated sample preparation, encompassing nucleic acid extraction using proven magneticparticle technology and PCR pipetting. Up to 96 primary samples from various […]

336

Siemens Healthineers to distribute Scopio Labs’ full-field digital cell morphology technology

Siemens Healthineers to distribute Scopio Labs’ full-field digital cell morphology technology Siemens Healthineers has agreed to distribute Scopio Labs’ full-field digital cell morphology technology, which will enable clinical labs to examine patient blood cell samples digitally instead of under a microscope. The Scopio X100 and Scopio X100HT imaging platforms will complement the Siemens Healthineers systems […]

338

Greiner Bio-One celebrates its 60th anniversary

Greiner Bio-One celebrates its 60th anniversary In 1963, the Greiner Bio-One division (then Greiner Laboratory Technology) was established within the Greiner Group to manufacture the first Petri dish made of plastic. On its 60th anniversary, the globally active company with German–Austrian roots can look back on its milestones and pioneering history. Greiner Bio-One, headquartered in […]

339

Gilead Sciences announces positive results from Veklury and obeldesivir trials

Gilead Sciences announces positive results from Veklury and obeldesivir trials Gilead Sciences, announced positive results from several COVID-19 clinical and real-world evidence studies presented at ECCMID. A Phase 3 clinical study demonstrated that Veklury (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which […]

340

Axcella Therapeutics presents results from Phase 2a clinical trial of AXA1125 for treatment of Long COVID Fatigue

Axcella Therapeutics presents results from Phase 2a clinical trial of AXA1125 for treatment of Long COVID Fatigue Axcella Therapeutics – a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions – gave two oral presentations of results from the Phase 2a clinical trial of AXA1125 in the […]